Table 1 Lipid mediators and their subsequent action on enzymes and receptors involved in the endocannabinoid system and endocannabinoidome.
Protein | Names* | Endocannabinoid system | Endocannabinoidome | |||
|---|---|---|---|---|---|---|
Lipid signalling mediators | ||||||
NAEs | 2-MAGs | NAEs | 2-MAGs | NAAs | ||
Enzymes | ||||||
Anabolic | NAPE-PLD | AEA | – | PEA, OEA, LEA and others | – | – |
ABHD4 | AEA | – | PEA, OEA, LEA and others | – | – | |
GDE1 | AEA | – | PEA, OEA, LEA and others | – | – | |
DAGL-⍺/β | – | 2-AG | PEA, OEA, LEA and others | 2-OG, 2-LG and others | – | |
Catabolic | FAAH | AEA | 2-AG | PEA, OEA, LEA, DHEA | – | NOleG, NAraG |
MAGL | – | 2-AG | – | 2-OG, 2-LG and others | – | |
ABHD6 | – | 2-AG | – | 2-OG, 2-LG and others | – | |
COX-2 | AEA | 2-AG | – | – | C20:4n6 amides | |
ABHD12 | – | 2-AG | – | 2-OG, 2-LG and others | – | |
Cannabinoid receptors | CB1 | AEA | 2-AG | – | – | – |
CB2 | AEA | 2-AG | EPEA, DHEA | – | – | |
G protein-coupled receptors | GPR6 | – | – | – | – | NAraG |
GPR18 | – | – | – | – | NAraG | |
GPR55 | AEA | 2-AG | PEA | – | – | |
GPR110 | – | – | DHEA | – | – | |
GPR119 | – | – | OEA, LEA | 2-OG, 2-LG | – | |
Peroxisome proliferator-activated receptors | PPAR-⍺ | – | – | PEA, OEA | 2-PG | NOleA, NOleG |
PPAR-γ | AEA, DHEA | – | – | – | – | |
Transient receptor potential channels | TRPV1 | AEA | 2-AG | OEA, LEA, DHEA | 2-OG, 2-LG | NATaus |
TRPV2 | – | – | OEA, LEA, as antagonists | – | – | |
TRPV3 | – | – | – | – | – | |
TRPV4 | – | – | – | – | NATaus | |
TRPA1 | – | – | – | – | – | |
TRPM8 | AEA, as antagonist | 2-AG, as antagonist | – | – | – | |